Zimmer Biomet price target lowered to $112 from $125 at RBC Capital

RBC Capital lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $125 and keeps an Outperform rating on the shares following Q1 results that “modestly” beat consensus. The firm told investors that Zimmer stock was down over 10% due to multiple factors, including U.S. knee growth, Q2 commentary, second half growth weighting, Paragon 28-related dilution and tariffs. RBC added it expects better opportunity ahead of Q3 earnings as the company enters 2H25 where growth will be aided by new products.